Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Amateur Traders Corner -- Ignore unavailable to you. Want to Upgrade?

To: rogermci® who wrote (17723)	12/28/2001 8:30:38 PM
From: Paul A	Respond to of 19633

Im with you on that thinking Roger.. of course, remember how volatil this one can be.. Best to accumulate in smmmmaaalll chunks : )

To: rogermci® who wrote (17723)	12/28/2001 9:10:35 PM
From: Tom Hua	Read Replies (1) \| Respond to of 19633

Roger, if IMCL opens down less than 10 pts, I'll be all over it, on the short side of course. I think we may see 30s on Monday. This $4 billion market cap company trades on the promise of a single drug and now all bets are off in the short term. If I do go long on a 20 pts dip, I won't take it home. Regards, Tom

To: rogermci® who wrote (17723)	12/31/2001 8:06:57 AM
From: Tom Hua	Read Replies (2) \| Respond to of 19633

Good morning Roger, IMCL down 10 pts at this time. I started a SS at 45.9. 07:50 ET Imclone Sys (IMCL) 55.25: -- Update -- UBS Warburg believes that the FDA request for more information on Erbitux will push back approval of the drug by at least 6 months. As a result, firm is pushing out its revenue stream for the drug to 2003 from 2002 and reducing price target to $62. In rejecting the filing, the FDA sited deficiencies in documentation of inclusion criteria and determination of response. IMCL will hold a conference call at 8:30 to discuss the FDA decision: 888-849-9221. Regards, Tom